company background image
OJU1 logo

Oramed Pharmaceuticals DB:OJU1 Stock Report

Last Price

€2.58

Market Cap

€105.9m

7D

0.4%

1Y

31.4%

Updated

28 Mar, 2024

Data

Company Financials +

Oramed Pharmaceuticals Inc.

DB:OJU1 Stock Report

Market Cap: €105.9m

OJU1 Stock Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides.

OJU1 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health3/6
Dividends0/6

Oramed Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oramed Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.58
52 Week HighUS$4.64
52 Week LowUS$1.60
Beta1.83
1 Month Change-19.86%
3 Month Change23.48%
1 Year Change31.43%
3 Year Change-70.22%
5 Year Change-14.50%
Change since IPO-72.41%

Recent News & Updates

Recent updates

Shareholder Returns

OJU1DE PharmaceuticalsDE Market
7D0.4%2.7%1.8%
1Y31.4%-24.4%5.7%

Return vs Industry: OJU1 exceeded the German Pharmaceuticals industry which returned -24.6% over the past year.

Return vs Market: OJU1 exceeded the German Market which returned 7% over the past year.

Price Volatility

Is OJU1's price volatile compared to industry and market?
OJU1 volatility
OJU1 Average Weekly Movement9.8%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market9.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: OJU1's share price has been volatile over the past 3 months.

Volatility Over Time: OJU1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2002n/aNadav Kidronhttps://www.oramed.com

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company’s product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.

Oramed Pharmaceuticals Inc. Fundamentals Summary

How do Oramed Pharmaceuticals's earnings and revenue compare to its market cap?
OJU1 fundamental statistics
Market cap€105.92m
Earnings (TTM)€5.12m
Revenue (TTM)€1.24m

21.4x

P/E Ratio

88.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OJU1 income statement (TTM)
RevenueUS$1.34m
Cost of RevenueUS$0
Gross ProfitUS$1.34m
Other Expenses-US$4.18m
EarningsUS$5.53m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.14
Gross Margin100.00%
Net Profit Margin412.31%
Debt/Equity Ratio31.3%

How did OJU1 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.